Cargando…
Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibroti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975385/ https://www.ncbi.nlm.nih.gov/pubmed/36873896 http://dx.doi.org/10.3389/fmed.2023.1114722 |
_version_ | 1784898862506311680 |
---|---|
author | Stanel, Stefan Cristian Rivera-Ortega, Pilar |
author_facet | Stanel, Stefan Cristian Rivera-Ortega, Pilar |
author_sort | Stanel, Stefan Cristian |
collection | PubMed |
description | Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future. |
format | Online Article Text |
id | pubmed-9975385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99753852023-03-02 Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases Stanel, Stefan Cristian Rivera-Ortega, Pilar Front Med (Lausanne) Medicine Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future. Frontiers Media S.A. 2023-02-15 /pmc/articles/PMC9975385/ /pubmed/36873896 http://dx.doi.org/10.3389/fmed.2023.1114722 Text en Copyright © 2023 Stanel and Rivera-Ortega. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Stanel, Stefan Cristian Rivera-Ortega, Pilar Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
title | Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
title_full | Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
title_fullStr | Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
title_full_unstemmed | Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
title_short | Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
title_sort | present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975385/ https://www.ncbi.nlm.nih.gov/pubmed/36873896 http://dx.doi.org/10.3389/fmed.2023.1114722 |
work_keys_str_mv | AT stanelstefancristian presentandfutureperspectivesinearlydiagnosisandmonitoringforprogressivefibrosinginterstitiallungdiseases AT riveraortegapilar presentandfutureperspectivesinearlydiagnosisandmonitoringforprogressivefibrosinginterstitiallungdiseases |